Citations

Mayo Clinic

Showing 10 of 108602 citations.

The Timing of Hip Arthroscopy After Intra‐articular Hip Injection Affects Postoperative Infection Risk
Coleman, Struan H. , Kelly, Bryan T. , Werner, Brian C. , Wang, Dean , Camp, Christopher L. , Ranawat, Anil S.

Arthroscopy | August 8, 2017 | Volume: 33 | Issue: 11 | Pages: 1988

10.1016/j.arthro.2017.06.037 | PMID 28800918 Get It

Purpose To evaluate the association of preoperative intra‐articular hip injection with surgical site infection after hip arthroscopy. Methods A large administrative database was used to identify all patients undergoing hip arthroscopy from 2007 to 2015 within a single private insurer and from 2005 to 2012 within Medicare in the United States. Those that received an ipsilateral preoperative intra‐articular hip injection were identified. The patients were then divided into the following groups based on the interval between preoperative injection and ipsilateral hip arthroscopy: (1) <3 months, (2) 3 to 6 months, and (3) 6 to 12 months. These groups were compared to a control group composed of patients with no history or a remote history (>12 months) of preoperative hip injection. Patients developing a surgical site infection within 6 months following hip arthroscopy were identified using International Classification of Diseases, Ninth Revision, and Current Procedural Terminology codes associated with infection. Groups were compared using a multivariate logistic regression analysis to control for age, gender, body mass index, smoking status, alcohol usage, and multiple medical comorbidities including diabetes mellitus, hemodialysis use, inflammatory arthritis, and peripheral vascular disease. Results In total, 19% of privately insured and 6% of Medicare patients received a hip injection within 12 months of hip arthroscopy. The overall infection rate in privately insured and Medicare patients was 1.19% and 1.10%, respectively. Preoperative hip injection within 3 months of surgery was associated with a significantly higher risk of postoperative infection versus controls (2.16%, odds ratio [OR] 6.1, P < .001, for privately insured group; 2.80%, OR 1.99, P = .037, for Medicare group). In contrast, preoperative hip injection given after more than 3 months of surgery was not associated with an increased risk of postoperative infection versus controls. Conclusions Risk of infection after hip arthroscopy increased when preoperative intra‐articular hip injections were given within 3 months of surgery. Level of Evidence Level III, retrospective comparative study.
The Future of Preventing and Treating Nipah Virus Infection
Satterfield, Benjamin A. , Satterfield, Benjamin A

Future Science OA | August 8, 2017 | Volume: 3 | Issue: 4 | Pages: No page available

10.4155/fsoa-2017-0056 Get It

Effect of Low- Versus High-Intensity Exercise Training on Biomarkers of Inflammation and Endothelial Dysfunction in Adolescents With Obesity: A 6-Month Randomized Exercise Intervention Study
Tenório, Thiago R.S., Balagopal, Prabhakaran , Ritti‐Dias, Raphael Mendes , Lofrano‐Prado, Mara Cristina , Prado, Wagner Luiz do , Balagopal, P Babu, Andersen, Lars Bo , Hill, James O.

Pediatric Exercise Science | August 8, 2017 | Volume: 30 | Issue: 1 | Pages: 96-105

10.1123/pes.2017-0067 | PMID 28787243 Get It

Purpose: To investigate the effects of a low- versus high-intensity aerobic training on biomarkers of inflammation and endothelial dysfunction in adolescents with obesity. Methods: Sixty-two adolescents with obesity [age = 15 (14) y, body mass index = 34.87 (4.22) kg·m−2] were randomized to receive either a high-intensity training (HIT, n = 31) or a low-intensity training (LIT, n = 31) for 24 weeks. All participants also received nutritional, psychological, and clinical counseling. Leptin, total and subtype leukocyte counts, tumor necrosis factor-alpha, interleukin-6, myeloperoxidase, soluble intercellular adhesion molecule-1, and soluble vascular cell adhesion molecule-1 were obtained at baseline and after 24 weeks. Results: HIT reduced neutrophils [from 4.4 (1.9) to 3.6 (1.3) µL−1 × 103; P = .01] and monocytes [from 7.2 (2.5) to 5.2 (1.8) µL−1 × 102; P < .01], but LIT increased neutrophils [from 4.5 (1.7) to 5.2 (3.3) µL−1 × 103; P = .01]. Although tumor necrosis factor-alpha increased in LIT [from 13.3 (7.5) to 17.7 (10.8) pg·mL−1; P = .01], it decreased in HIT [from 12.4 (7.5) to 11.3 (6.2) pg·mL−1; P = .01]. No changes in leukocyte counts, soluble intercellular adhesion molecule-1, soluble vascular cell adhesion molecule-1, and homeostasis assessment model for insulin resistance were observed. Conclusions: Both HIT and LIT improved the inflammatory profile. The study, however, indicated that the number of biomarkers and the magnitude of changes were higher in the HIT compared with LIT.
Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment‐naïve patients with Waldenstrom macroglobulinemia
Paludo, Jonas , Abeykoon, Jithma P. , Kumar, Shaji , Shreders, Amanda , Kourelis, Taxiarchis , King, Rebecca L. , Reeder, Craig B. , Kyle, Robert A. , Dingli, David , Lacy, Martha Q. , Lin, Yi , Warsame, Rahma , Lust, John A., Ansell, Stephen M. , Kapoor, Prashant , Buadi, Francis K. , Gonsalves, Wilson , Paludo, Jonas , Dingli, David , Lin, Yi , Ailawadhi, Sikander , Gertz, Morie A. , Leung, Nelson , Habermann, Thomas M. , Witzig, Thomas E. , Dispenzieri, Angela , Go, Ronald S. , Gonsalves, Wilson I. , Rajkumar, S. Vincent

British Journal of Haematology | August 8, 2017 | Volume: 179 | Issue: 1 | Pages: 98-105

10.1111/bjh.14826 | PMID 28786474 Get It

SummaryThe management of Waldenström macroglobulinaemia (WM) relies predominantly on small trials, one of which has demonstrated activity of dexamethasone, rituximab and cyclophosphamide (DRC) in the frontline setting. We report on the efficacy of DRC, focusing on relapsed/refractory (R/R) patients. Ibrutinib, a recently approved agent in WM demonstrated limited activity in patients with MYD88WT genotype. Herein, we additionally report on the activity of DRC based on the MYD88L265P mutation status. Of 100 WM patients evaluated between January 2007 and December 2014 who received DRC, 50 had R/R WM. The overall response rate (ORR) was 87%. The median progression‐free survival (PFS) and time‐to‐next‐therapy (TTNT) were 32 (95% confidence interval [CI]: 15–51) and 50 (95% CI: 35–60) months, respectively. In the previously untreated cohort (n = 50), the ORR was 96%, and the median PFS and TTNT were 34 months (95% CI: 23–not reached [NR]) and NR (95% CI: 37–NR), respectively. Twenty‐five (86%) of 29 genotyped patients harbored MYD88L265P. The response rates and outcomes were independent of MYD88 mutation status. Grade ≥3 adverse effects included neutropenia (20%), thrombocytopenia (7%) and infections (3%). Similar to the frontline setting, DRC is an effective and well‐tolerated salvage regimen for WM. In contrast to ibrutinib, DRC offers a less expensive, fixed‐duration option, with preliminary data suggesting efficacy independent of the patients’ MYD88 status.
Diagnostic Yield of Whole Exome Sequencing in Pediatric Dilated Cardiomyopathy
Long, Pamela A., Evans, Jared M., Olson, Timothy M.

Journal of Cardiovascular Development and Disease | August 8, 2017 | Volume: 4 | Issue: 3 | Pages: 11

10.3390/jcdd4030011 | PMID 29367541 Get It

Dilated cardiomyopathy (DCM) is a heritable, genetically heterogeneous disorder characterized by progressive heart failure. DCM typically remains clinically silent until adulthood, yet symptomatic disease can develop in childhood. We sought to identify the genetic basis of pediatric DCM in 15 sporadic and three affected-siblings cases, comprised of 21 affected children (mean age, five years) whose parents had normal echocardiograms (mean age, 39 years). Twelve underwent cardiac transplantation and five died with severe heart failure. Parent-offspring whole exome sequencing (WES) data were filtered for rare, deleterious, de novo and recessive variants. In prior work, we reported de novo mutations in TNNT2 and RRAGC and compound heterozygous mutations in ALMS1 and TAF1A among four cases in our cohort. Here, de novo mutations in established DCM genes—RBM20, LMNA, TNNT2, and PRDM16—were identified among five additional cases. The RBM20 mutation was previously reported in familial DCM. An identical unreported LMNA mutation was identified in two unrelated cases, both harboring gene-specific defects in cardiomyocyte nuclear morphology. Collectively, WES had a 50% diagnostic yield in our cohort, providing an explanation for pediatric heart failure and enabling informed family planning. Research is ongoing to discover novel DCM genes among the remaining families.
Automated Measurement of Patient-Specific Tibial Slopes from MRI
Amerinatanzi, Amirhesam , Summers, Rodney K., Ahmadi, Kaveh, Hewett, Timothy E. , Nyman, Edward , Goel, Vijay K.

Bioengineering | August 8, 2017 | Volume: 4 | Issue: 3 | Pages: 69

10.3390/bioengineering4030069 | PMID 28952547 Get It

Background: Multi-planar proximal tibial slopes may be associated with increased likelihood of osteoarthritis and anterior cruciate ligament injury, due in part to their role in checking the anterior-posterior stability of the knee. Established methods suffer repeatability limitations and lack computational efficiency for intuitive clinical adoption. The aims of this study were to develop a novel automated approach and to compare the repeatability and computational efficiency of the approach against previously established methods. Methods: Tibial slope geometries were obtained via MRI and measured using an automated Matlab-based approach. Data were compared for repeatability and evaluated for computational efficiency. Results: Mean lateral tibial slope (LTS) for females (7.2°) was greater than for males (1.66°). Mean LTS in the lateral concavity zone was greater for females (7.8° for females, 4.2° for males). Mean medial tibial slope (MTS) for females was greater (9.3° vs. 4.6°). Along the medial concavity zone, female subjects demonstrated greater MTS. Conclusion: The automated method was more repeatable and computationally efficient than previously identified methods and may aid in the clinical assessment of knee injury risk, inform surgical planning, and implant design efforts.
Fast Approximation Methods for Online Scheduling of Outpatient Procedure Centers
Berg, Bjorn P. , Denton, Brian T.

INFORMS Journal on Computing | August 8, 2017 | Volume: 29 | Issue: 4 | Pages: 631-644

10.1287/ijoc.2017.0750 Get It

This paper presents a new model for online decision making. Motivated by the healthcare delivery application of dynamically allocating patients to procedure rooms in outpatient procedure centers, the online stochastic extensible bin-packing problem is described. The objective is to minimize the combined costs of opening procedure rooms and utilizing overtime to complete a day’s procedures. The dynamic patient-allocation decisions are made in an uncertain environment where the number of patients scheduled and the procedure durations are not known in advance. The resulting optimization model’s tractability focuses the paper’s attention on approximation methods and a special case that is amenable to decomposition-based solution methods. Theoretical performance guarantees are presented for list-based approximation methods as well as an approximation that is common in practice, where procedure rooms are reserved for patient groups in advance. Numerical results based on a real outpatient procedure center demonstrate the favorable results of the list-based approximations based on their average and worst case performances, as well as their computational requirements. Further, the numerical experiments show that the policy of reserving procedure rooms for patient groups in advance can perform poorly. These results are contrary to common practice and favor alternative, and still easy-to-implement, policies. The online supplement is available at https://doi.org/10.1287/ijoc.2017.0750 .
Submillimeter alignment of more than three contiguous vertebrae in spinal SRS/SBRT with 6‐degree couch
Luo, Dershan , Yang, James N., Yang, Jinzhong , Chang, Eric L. , Brown, Paul D. , McAleer, Mary Frances , Ghia, Amol J. , Wang, Xin , Zhao, Zhongxiang , Li, Jing , Yang, Jinzhong

Journal of Applied Clinical Medical Physics | August 8, 2017 | Volume: 18 | Issue: 5 | Pages: 225-236

10.1002/acm2.12153 | PMID 28786235 Get It

AbstractThe purpose of this study is to identify regions of spinal column in which more than three contiguous vertebrae can be reliably and quickly aligned within 1 mm using a 6‐degree (6D) couch and full body immobilization device. We analyzed 45 cases treated over a 3‐month period. Each case was aligned using ExacTrac x‐ray positioning system with integrated 6D couch to be within 1° and 1 mm in all six dimensions. Cone‐Beam computed tomography (CBCT) with at least 17.5 cm field of view (FOV) in the superior–inferior direction was taken immediately after ExacTrac positioning. It was used to examine the residual error of five to nine contiguous vertebrae visible in the FOV. The residual error of each vertebra was determined by expanding/contracting the vertebrae contour with a margin in millimeter integrals on the planning CT such that the new contours would enclose the corresponding vertebrae contour on CBCT. Submillimeter initial setup accuracy was consistently achieved in 98% (40/41) cases for a span of five or more vertebrae starting from T2 vertebra and extending caudally to S5. The curvature of spinal column along the cervical region and cervicothoracic junction was not easily reproducible between treatment and simulation. Fifty‐seven percent (8/14) of cases in this region had residual setup error of more than 1 mm in nearby vertebrae after alignment using 6D couch with image guidance. In conclusion, 6D couch integrated with image guidance is convenient and accurately corrects small rotational shifts. Consequently, more than three contiguous vertebrae can be aligned within 1 mm with immobilization that reliably reproduces the curvature of the thoracic and lumbar spinal column. Ability of accurate setup is becoming less a concern in limiting the use of stereotactic radiosurgery or stereotactic body radiation therapy to treat multilevel spinal target.
Glucose Homeostasis, Pancreatic Endocrine Function, and Outcomes in Advanced Heart Failure
Melenovský, Vojtěch , Beneš, Jan , Franeková, Janka , Kovar, Jan, Borlaug, Barry A. , Segeťová, Markéta , Pelikánová, T, Borlaug, Barry A , Kovář, Jan , Tura, Andrea , Melenovský, Vojtěch

Journal of the American Heart Association | August 8, 2017 | Volume: 6 | Issue: 8 | Pages: No page available

10.1161/jaha.116.005290 | PMID 28784650 Get It

Background The mechanisms and relevance of impaired glucose homeostasis in advanced heart failure ( HF ) are poorly understood. The study goals were to examine glucose regulation, pancreatic endocrine function, and metabolic factors related to prognosis in patients with nondiabetic advanced HF. Methods and Results In total, 140 advanced HF patients without known diabetes mellitus and 21 sex‐, age‐, and body mass index–matched controls underwent body composition assessment, oral glucose tolerance testing, and measurement of glucose‐regulating hormones to model pancreatic β‐cell secretory response. Compared with controls, HF patients had similar fasting glucose and insulin levels but higher levels after oral glucose tolerance testing. Insulin secretion was not impaired, but with increasing HF severity, there was a reduction in glucose, insulin, and insulin/glucagon ratio—a signature of starvation. The insulin/C‐peptide ratio was decreased in HF , indicating enhanced insulin clearance, and this was correlated with lower cardiac output, hepatic insufficiency, right ventricular dysfunction, and body wasting. After a median of 449 days, 41% of patients experienced an adverse event (death, urgent transplant, or assist device). Increased glucagon and, paradoxically, low fasting plasma glucose displayed the strongest relations to outcome ( P =0.01). Patients in the lowest quartile of fasting plasma glucose (3.8–5.1 mmol·L −1 , 68–101 mg·dL −1 ) had 3‐times higher event risk than in the top quartile (6.0–7.9 mmol·L −1 , 108–142 mg·dL −1 ; relative risk: 3.05 [95% confidence interval, 1.46–6.77]; P =0.002). Conclusions Low fasting plasma glucose and increased glucagon are robust metabolic predictors of adverse events in advanced HF . Pancreatic insulin secretion is preserved in advanced HF , but levels decrease with increasing HF severity due to enhanced insulin clearance that is coupled with right heart failure and cardiac cachexia.
Double‐blind, randomized phase 3 trial of low‐dose 13‐cis retinoic acid in the prevention of second primaries in head and neck cancer: Long‐term follow‐up of a trial of the Eastern Cooperative Oncology Group‐ACRIN Cancer Research Group (C0590)
Bhatia, Aarti , Lee, Ju‐Whei, Pinto, Harlan A. , Jacobs, Charlotte, Rubin, Philip, Arusell, Robert M., Dunphy, Eamonn P., Khandekar, Janardan D., Reiner, Seth A., Báez-Díaz, Luis , Celano, Paul , Li, Yi , Burtness, Barbara , Adams, George L. , Pandya, Kishan J., Bhatia, Aarti K , Limburg, Paul J. , Burtness, Barbara , Lee, Ju‐Whei , Li, Shuli

Cancer | August 7, 2017 | Volume: 123 | Issue: 23 | Pages: 4653-4662

10.1002/cncr.30920 | PMID 28786105 Get It

BACKGROUND13‐Cis retinoic acid (13‐CRA) is a synthetic vitamin A derivative. High‐dose 13‐CRA in patients with squamous cell cancers of the head and neck (SCCHNs) reduces the incidence of second primary tumors (SPTs). The authors report long‐term results from a phase 3 randomized trial that compared treatment with low‐dose 13‐CRA versus placebo for patients who had early stage SCCHN, with a focus on the development of SPTs and overall survival (OS).METHODSIn total, 176 patients who received treatment for stage I/II SCCHN were randomized to receive either low‐dose 13‐CRA (weight‐based dose of 7.5 mg or 10 mg) or placebo for 2 years. A competing‐risk approach and the log‐rank test were used to compare the time to SPT and OS, respectively, between groups.RESULTS13‐CRA neither significantly reduced the cumulative incidence of SPT (P = .61) nor improved the time to SPT (hazard ratio [HR] for 13‐CRA/placebo; 0.86; P = .61). Despite limited power, there was a trend toward improved OS for the 13‐CRA arm (HR, 0.75; P = .14), particularly among patients whose index tumor was surgically excised (N = 26; HR, 0.50; P = .057) and among women (N = 39; HR, 0.44; P = .065) and never/former smokers (N = 129; HR, 0.61; P = .055), with a median follow‐up of 16 years. The main 13‐CRA related toxicities were dry skin and cheilitis.CONCLUSIONSTreatment with low‐dose 13‐CRA for 2 years did not decrease the incidence of SPT; subset analysis indicates a potential survival advantage among patients who are women and never/former smokers. More targeted interventions based on clinical risk factors and molecular characterization of tumors may yield greater success in future prevention trials. Cancer 2017;123:4653‐4662. © 2017 American Cancer Society.